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We read with interest the article by Oktay et al. [1], which
purports that gonadotropin-releasing hormone (GnRH) an-
alogue treatment for protection against chemotherapy-in-
duced ovarian damage is ineffective.
Though we firmly agree that randomized controlled tri-
als are necessary to confirm GnRH analogue cotreatment
efficacy, the preponderance of available evidence is very
encouraging. A recent meta-analysis, inclusive of 320 pa-
tients from seven controlled studies, found GnRH agonist
use during chemotherapy to be significantly associated with
ovarian function preservation (relative risk, 1.7; 95% con-
fidence interval, 1.4–2.2) [2].
We would like to specifically address several comments
in the review by Oktay et al. [1] relevant to our published
trial of leuprolide acetate in systemic lupus erythematosus
(SLE) patients undergoing cyclophosphamide (CYC) ther-
apy [3].
Oktay et al. [1] questioned our use of the absence of pre-
mature ovarian failure as our primary outcome (defined as
menses in the preceding 12 months and a follicle-stimulat-
ing hormone level 40 mIU/ml) because we did not assess
fertility. We argue that the presence of menses is a valid in-
dication of intact ovarian function, albeit without the ability
to assess gradations of ovarian reserve. Though fertility po-
tential/fecundity are of interest, there are logistical and eth-
ical constraints in using these as primary endpoints,
because they restrict the eligible study population to women
planning to attempt conception within a defined time frame
post-chemotherapy.
Oktay et al. [1] were critical of our protocol’s use of
add-back estrogen in patients receiving GnRH analogues,
although we view this as a strength in that our study was
able to demonstrate, for the first time, that the potential pro-
tective effect of GnRH analogues did not result from a hy-
poestrogenic environment.
As we discussed, our controls had, on average, 1.5 years
longer SLE duration and potentially greater lupus severity
than patients in the GnRH analogue group. However, given
the fact that all GnRH analogue–treated and control patients
in our study had SLE activity warranting i.v. CYC therapy,
and the lack of evidence or plausibility suggesting that the
severity of lupus affects the development of CYC-induced
ovarian damage, we do not believe that these issues impact
the overall interpretation of our findings.
Finally, the authors were critical of our use of survival
analysis, in part because of their post hoc calculation of
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power. Post hoc power calculation is not only a controver-
sial statistical practice [4], but is irrelevant when the null
hypothesis has already been rejected, indicating the ability
to detect a statistical difference between groups. Oktay et al.
[1] further state that because there was only one case of pre-
mature ovarian failure in our GnRH analogue–treated
group, it is hard to make a statistical argument. Clearly, sta-
tistical testing is designed to support or refute qualitative as-
sessments.
The state of available evidence indicates that GnRH an-
alogue therapy for the prevention of CYC-induced ovarian
injury has strong potential as a safe, cost-effective, and eas-
ily administered method for ovarian preservation in women
undergoing chemotherapy for various indications. With a
range of comorbidities known to be associated with prema-
ture ovarian failure (e.g., cardiovascular disease, osteopo-
rosis, depression), the ultimate therapeutic goal should be
the preservation of normal ovarian function, not solely sal-
vaging reproductive potential.
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